Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lineage Therap ( (LCTX) ) has provided an update.
Lineage Cell Therapeutics announced the closing of the second tranche of its registered direct offering on January 27, 2025, following shareholder approval. The company has received $30 million in gross proceeds so far, with the potential for an additional $36 million from clinical milestone-linked warrants. The funds will be used for working capital, general corporate purposes, research, and development.
More about Lineage Therap
Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing ‘off-the-shelf’ cell therapies for unmet medical needs using a proprietary cell-based technology platform. The company’s pipeline includes therapies for geographic atrophy, spinal cord injuries, auditory neuropathy, and vision loss, among others, in collaboration with partners like Roche and Genentech.
YTD Price Performance: 23.50%
Average Trading Volume: 2,528,577
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $140.2M
For an in-depth examination of LCTX stock, go to TipRanks’ Stock Analysis page.
